Will Hexo Continue to Struggle in 2020?
For the second quarter of fiscal 2020, analysts expect Hexo's revenue to grow 25.5% YoY (year-over-year) to 16.8 million Canadian dollars.
Is Cresco Labs a Good Bet in January?
Analysts expect Cresco Labs to report revenues of $45.3 million in the fourth quarter to take the total revenue for 2019 to $131.9 million.
Why Beacon Securities Is Bullish on Curaleaf
On Monday, Russell Stanley of Beacon Securities reiterated his "buy" rating for Curaleaf Holdings. He gave a target price of 25 Canadian dollars.
Vermont Could See Marijuana Sales in 2020
Marijuana is legal in Vermont for medical and recreational use. However, there are some limitations. The state doesn't allow marijuana sales yet.
Why Is Aphria’s EU GMP Certification a Big Deal?
Yesterday, Aphria announced that it received GMP (Good Manufacturing Practices) certification from the EU for its subsidiary Avanti Rx Analytics.
Missouri Wants to Legalize Marijuana in 2020
Marijuana for adult-use is illegal in Missouri. The residents have stepped up to get recreational marijuana legalization on the November 2020 ballot.
Why Jefferies Went Bearish on Aphria and Bullish on OGI
On Monday, Jefferies reduced the target price for Aphria stock to 10.3 Canadian dollars from 11 Canadian dollars. Why is Jefferies bearish?
Is Charlotte’s Web Still a Good Buy?
Although 2019 was tough for Charlotte’s Web Holdings, it has made a significant recovery this year. The stock has increased by 14.8% YTD as of Monday.
OrganiGram: Analysts’ Ratings and Target Prices after Q1 Earnings
As of Monday, OrganiGram Holdings (OGI) was trading at 4.21 Canadian dollars—a rise of 49.8% since reporting its first-quarter earnings on January 14.